SK Biopharm "Aiming to Double Performance in All Business Areas This Year... Leap to a Global Healthcare Company"

Jung Wooh Cho, CEO of SK Biopharm, is holding an online press conference on the 24th.

[Asia Economy Reporter Lee Gwan-joo] SK Biopharm plans to double the sales of its flagship innovative epilepsy drug 'Cenobamate' this year and expand its presence in the global market.

On the 24th, Cho Jung-woo, CEO of SK Biopharm, revealed this plan during an online press conference and presented the goal of growing into a 'global healthcare company.'

SK Biopharm announced that it aims to achieve double the performance compared to the previous year across all business areas, including ▲increased US sales of Cenobamate ▲expanded global market entry ▲accelerated product launches and introductions ▲expanded cooperation with promising external companies.

This year, SK Biopharm targets Cenobamate sales exceeding 160 billion KRW and achieving the number one recognition for epilepsy drugs. Based on its strength in the 'seizure freedom rate,' the company plans to shift disease awareness and treatment paradigms, engaging in comprehensive activities such as expanding online and cable TV advertising and strengthening face-to-face sales and marketing.

The global market expansion of Cenobamate will continue. The company is pursuing technology exports to South America and plans to launch the drug in major European countries such as France, Italy, Switzerland, and Spain through its partner Angelini Pharma. Korea, China, and Japan are targeting a 2025 launch, accelerating Phase 3 clinical trials.

At the same time, SK Biopharm is focusing on the development of next-generation innovative drugs. 'Carisbamate,' a treatment for Lennox-Gastaut syndrome, has entered Phase 3 clinical trials; targeted anticancer drug SKL27969 is in Phase 1; and next-generation epilepsy drug SKL24741 and schizophrenia drug SKL20540 are preparing for Phase 2 trials.

SK Biopharm plans to evolve into a healthcare company covering the entire cycle from prevention and diagnosis to treatment. It is actively advancing clinical trials for epilepsy prediction and detection devices, integrating innovative technologies such as protein degradation and miRNA, investing in global bio funds, and establishing strategic relationships with promising overseas digital therapeutics ventures.

The company also shared plans to enhance ESG management. It will expand the scope of implementation to its US subsidiary and establish a governance system at a global level. Last month, SK Biopharm became the first in the domestic pharmaceutical and bio industry to join the global initiative PSCI to respond to and manage supply chain risks among partners.

CEO Cho Jung-woo stated, “We will accelerate growth by expanding the business area and increasing sales of Cenobamate, continuously launch new products, and strengthen competitiveness and leadership in the market. Along with innovative drug development, we will expand our portfolio into the digital therapeutics field to provide comprehensive solutions to patients and healthcare professionals.”

This content was produced with the assistance of AI translation services.